MX2023006690A - Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos. - Google Patents

Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos.

Info

Publication number
MX2023006690A
MX2023006690A MX2023006690A MX2023006690A MX2023006690A MX 2023006690 A MX2023006690 A MX 2023006690A MX 2023006690 A MX2023006690 A MX 2023006690A MX 2023006690 A MX2023006690 A MX 2023006690A MX 2023006690 A MX2023006690 A MX 2023006690A
Authority
MX
Mexico
Prior art keywords
inhibitor
egfr
methods
compositions
solid tumors
Prior art date
Application number
MX2023006690A
Other languages
English (en)
Inventor
Jennifer Lee Schutzman
Marie Evangelista
Mark Andrew Merchant
Ting- Kun Mark Lin
Stephanie Royer Joo
Sandhya Vinayak Mandlekar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023006690A publication Critical patent/MX2023006690A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan politerapias que comprenden un inhibidor de KRasG12C (por ejemplo, Compuesto 1) y un inhibidor de EGFR y procedimientos de uso de dichas politerapias.
MX2023006690A 2020-12-08 2021-12-06 Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos. MX2023006690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063122702P 2020-12-08 2020-12-08
PCT/US2021/061980 WO2022125427A1 (en) 2020-12-08 2021-12-06 Methods and compositions comprising a krasg12c inhibitor and a egfr-inhibitor for treating solid tumors

Publications (1)

Publication Number Publication Date
MX2023006690A true MX2023006690A (es) 2023-06-19

Family

ID=79601969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006690A MX2023006690A (es) 2020-12-08 2021-12-06 Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos.

Country Status (11)

Country Link
US (1) US20220193077A1 (es)
EP (1) EP4259146A1 (es)
JP (1) JP2024500326A (es)
KR (1) KR20230116899A (es)
CN (1) CN116568306A (es)
AU (1) AU2021397214A1 (es)
CA (1) CA3204191A1 (es)
IL (1) IL303448A (es)
MX (1) MX2023006690A (es)
TW (1) TW202228699A (es)
WO (1) WO2022125427A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150706A1 (en) * 2022-02-07 2023-08-10 Genentech, Inc. Solid forms of 1-((s)-4-((r)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((s)-1- methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3- methylpiperazin-1-yl)prop-2-en-1-one

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
JP2022500379A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
KR20230147742A (ko) * 2018-11-09 2023-10-23 에프. 호프만-라 로슈 아게 축합 고리 화합물
JP7377679B2 (ja) * 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法

Also Published As

Publication number Publication date
CA3204191A1 (en) 2022-06-16
IL303448A (en) 2023-08-01
AU2021397214A1 (en) 2023-07-06
JP2024500326A (ja) 2024-01-09
KR20230116899A (ko) 2023-08-04
EP4259146A1 (en) 2023-10-18
CN116568306A (zh) 2023-08-08
WO2022125427A1 (en) 2022-06-16
TW202228699A (zh) 2022-08-01
US20220193077A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
CR20220258A (es) Inhibidores de kras g12c
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
EP4268898A3 (en) Kras g12c inhibitors for treating cancer
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CL2020002405A1 (es) Inhibidores de kras g12c y métodos para su uso (divisional de la solicitud no. 201903394)
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2020007947A (es) Inhibidores de erbb/btk.
MX2023006690A (es) Procedimientos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de egfr para el tratamiento de tumores solidos.
CY1106423T1 (el) Ενωσεις ισοϊνδολο-ιμιδιου, συνθεσεις και χρησεις αυτων
WO2023004102A3 (en) Compositions and methods for inhibition of ras
MX2022003537A (es) Terapias de combinacion.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022010944A (es) Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
MX2021002805A (es) Terapias de combinacion.
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
ATE528286T1 (de) 4-ä4-ä(ä3-tert-butyl-1-ä3-(hydroxymethyl)phenyl - 1h-pyrazol-5-ylücarbamoyl)-aminoü-3- chlorophenoxyü-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
TW202423446A (zh) 用於治療實性瘤之包含 krasg12c 抑制劑及 egfr 抑制劑之組成物及方法
CR20230203A (es) Un inhibidor de magl
ZA202106519B (en) Caspase inhibitors and methods of use thereof
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
MX2023005529A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un inhibidor de vegf para tratar tumores solidos.
WO2023122260A3 (en) Inhibitors of sars-cov-2